Dr. Marinov - Core Peptides — Peptide Therapy Guide

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Dr. Marinov (MD, Ph.D.)

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals.

As both a medical doctor and a scientist, Dr. Marinov possesses a combination of deep knowledge in medicine & health with excellent research skills. You can learn more about his work and experience on his website, ResearchGate page, and LinkedIn profile.

Latest Articles by Dr. Marinov

Thymogen Potential in Immune Cell Regulation

Jul 17, 2026

Thymogen appears to be a synthetic dipeptide composed of the two amino acids L-glutamine and L-tryptophan (Glu-Trp). It was originally identified by a team of researchers led by Khavinson et al.,...

CJC-1295 & Hexarelin Blend Potential for Growth Hormone Signaling Stimulation

Jul 8, 2026

Researchers investigating growth hormone (GH) regulation in mammalian research models may consider experiments combining peptides that engage somatotroph cells of the anterior pituitary through...

Oxytocin Actions On Neuronal Circuits in Different Mammalian Research Models

Jun 30, 2026

Oxytocin is posited to be a cyclic nonapeptide composed of nine amino acids in the sequence Cys–Tyr–Ile–Gln–Asn–Cys–Pro–Leu–Gly-NH2 (CYIQNCPLG-NH2), with a molecular weight of approximately 1007 Da....

Kisspeptin 45-54 Peptide Interactions with Hypothalamic and Neuronal Cells

Jun 19, 2026

Kisspeptin 45-54 is posited to be a synthetic, 10–amino acid research peptide that is also referred to as kisspeptin 10. It may correspond to residues 45–54 of the parent kisspeptin precursor, and...

T-31 Peptide Interactions with Cellular Aging, Renewal, and Stress Pathways

May 28, 2026

T-31 is posited to be a synthetic, three–amino acid research peptide consisting of the sequence Ala-Glu-Asp (AED), and is also sometimes referred to in the literature as Cartalax. Structurally, it...

PNC-27 Peptide Interactions with Different Tumor Cell Lines

May 20, 2026

PNC-27 is posited to be a synthetic, 32–amino acid research peptide composed of two main segments. Specifically, its N-terminus appears to be made of a p53-derived HDM-2–binding sequence which...

Tesamorelin’s Potential for Anabolic and Catabolic Signaling in Cells

May 11, 2026

Tesamorelin is considered to be a synthetic analog of growth hormone-releasing hormone (GHRH), designed to activate GHRH receptors in pituitary gland cells. The peptide consists of the full...

Pal-AHK Interactions with Follicular Cells Growth and Apoptosis

May 6, 2026

Pal-AHK appears to be a tripeptide with the sequence alanine–histidine–lysine, which has been palmitoylated via a C16 fatty acid chain to the N-terminus of the sequence.(1) The peptide sequence...

Interactions Between PE-22-28 and Nerve Cells

Apr 30, 2026

PE-22-28 is a 7-amino-acid peptide derived from the degradation products of spadin (PE 12-28), which itself originates from the post-translational maturation of sortilin. Researchers have posited...

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

PSPeptides vs Core Peptides: A Direct Comparison

The most useful way to evaluate core peptides alternatives is a direct, factor-by-factor comparison. The table below shows how PSPeptides stacks up against Core Peptides across the criteria…

Source: pspeptides.com

Research context

Read sources and limitations before applying a claim.

Research

Researchers generally cease Hexarelin exposure within 2 weeks of initial introduction, as seen on average within the body of research on animal models. Doing otherwise was reported in some studies to potentially lead to an insignificant rise in growth hormone production due to, potentially, an increase in desensitization. A study opposing this practice was conducted. The experiment was performed on animal research subjects to examine Hexarelin’s desensitization rate in daily exposure. The subjects’ blood was drawn four times over 16 weeks and analyzed. Upon evaluation, the researchers concluded that Hexarelin appeared to have presented an insignificant difference in desensitization after the first and fourth week of exposure. Animal subjects exposed to Hexarelin reportedly presented muscle size increases, likely resulting from new myocytogenesis. Hexarelin also displayed accelerated injury recovery and, in some cases, was observed to have benefited cardiac functioning. Animal subjects without the ability to generate their own hGH naturally, were observed over the course of the study. The peptide has also been researched for its potential to increase epidermal elasticity, and has been suggested by researchers to exhibit properties that encompass possible injury prevention through increased epidermal structure and strength, and hastened recovery in damaged tissue. Hexarelin has been suggested to provide a variety of properties, with its most prominent potential actions speculated within the realm of fat regulation, cardiac protection, and muscle mass preservation. Initial research supports Hexarelin’s potential as a CD36 agonist, a protein involved in lipolysis control, and management of fatty acid breakdown. Exposure of cultured murine adipose to Hexarelin reportedly resulted in CD36 activation, which scientists reported drew out the reduced expression of PEPCK.(2) Since PEPCK is linked to the breakdown of fatty acids, this implies that this process may be regulated by CD36, and may potentially be thus activated by this peptide. Abnormal amounts of fat in the blood are referred to as dyslipidemia. Rodent research suggests that growth hormone-releasing peptide 6 (GHRP-6) may potentially inhibit dyslipidemia in an insulin resistance setting while lowering blood sugar and insulin resistance. Hexarelin may potentially provide an alternative to the lipid compounds currently widespread in research studies within the context of severe dyslipidemia.

Source: corepeptides.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →